Company / Revenue
Ultragenyx Pharmaceutical Inc. Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$673.0M
FY2025
5-year range
$103.7M / $673.0M
FY2021-FY2025
Trend
+20.2%
vs FY2024
Sector context
#55 of 155
Health Care
What the data says
At $673M, Ultragenyx Pharmaceutical Inc.'s revenue ranks #55 of 155 in the Health Care sector. Revenue has increased for 6 consecutive years, from $3M in FY2019 to $673M in FY2025.
Based on SEC 10-K filings.
$673M in FY2025 with a 5-year CAGR of +67.2%.
Improved from $434M to $673M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +22.8%
- 5-Year CAGR
- +67.2%
- 10-Year CAGR
- -
Sector benchmark
#55 of 155 in Health CareTop 35% of 155This company $673.0M Sector average $4.5B
▼
-84.9% below sector average
Key checks
Key Insights
- Ultragenyx Pharmaceutical Inc.'s revenue has grown for 6 consecutive years.
- 5-year CAGR of +67.2%, indicating consistent growth.
- In FY2025, revenue increased 20.2% year-over-year.
- Ranks #55 out of 155 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $673.0M | +20.2% |
| FY2024 | $560.0M | +29.0% |
| FY2023 | $434.0M | +19.5% |
| FY2022 | $363.3M | +250.3% |
| FY2021 | $103.7M | +101.4% |
| FY2020 | $51.5M | +1871.5% |
| FY2019 | $2.6M | -94.9% |
| FY2018 | $51.5M | +38618.0% |
| FY2017 | $133.0K | +682.4% |
| FY2016 | $17.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026